This opportunity is no longer accepting applications.
grant NIH/NCI 472

Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer

This grant opportunity supports the development of an innovative treatment approach using antibody-drug conjugates (ADCs) combined with radionuclides for cancer therapy. The project aims to overcome the limitations of ADCs, such as cancer resistance and ineffective drug delivery, by adding radionuclides that enable diagnostic imaging and enhance therapeutic effects. The use of diagnostic radio…

Fast-Track proposals will be accepted.\nDirect-to-Phase II proposals will be accepted.\nNumber of anticipated awards: 3-5\nBudget (total costs, per award):\nPhase I: up to $400,000 for up to 12 months\nPhase II: up to $2,250,000 for up to 2 years\nPROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURA…

Funding Source

Agency: National Institutes of Health
Program: SBIR

Dates

Opportunity Released: August 2, 2024
Open for Submission: August 2, 2024
Application Window Closes: October 18, 2024

Documents

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.